An observational study in Brain Aneurysm, sponsored by Mizuho Corporation. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Mizuho Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Intracranial Aneurysm with a site in Germany — 9 open to participants now, 14 under way, none of them phase 3. Intracranial Aneurysm · Germany.
Among the 46 studies in Intracranial Aneurysm with a site in Germany, this one is the 22nd largest by planned enrollment of the 32 observational ones that give a count, is the only one that started in 2025, is one of 33 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 44th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →9 of the 46 studies in Intracranial Aneurysm with a site in Germany are open now. Recruiting first, the newest first:
Phenox GmbH · Sites in Germany, France, Italy and 2 more countries
LuSeed Vascular LTD. · Sites in Germany, Bulgaria, Israel and 1 more country
Ages 18–80
Acandis GmbH · Sites in Germany
Ages 18+
Balt Extrusion · Sites in Germany, France, Spain
Ages 2+
Medical University of South Carolina · Sites in Germany, United States, Canada and 6 more countries
Ages 1–120
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 38 across the 13 interventional studies, 206 across the 32 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 46 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Mizuho Corporation as lead sponsor.
Mizuho Corporation has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
2 of the studies in Intracranial Aneurysm with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06761365LuSeed Vascular LTD.LUMENS-1 EU EFS CIP | 2026-12 |
| NCT06798740Mizuho CorporationPost Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices | 2027-02-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Intracranial Aneurysm with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to verify the performance and safety of the Sugita Aneurysm Clips devices when used as intended and to identify possible risk factors. Data collected will be used to support the continuing performance and safety of the devices in the post-market use environment in Europe. Subjects who have an intracranial aneurysm that the physician intends to treat with the subject devices will be included in the study. Subjects will be followup as per hospital standard of care for 5 years.
Subjects who have an intracranial aneurysm (ruptured or unruptured) that the physician intends to treat with the subject device(s)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients presenting intracranial aneurysm (ruptured or unruptured) that the physician intends to treat with the Sugita clips.
Device: Sugita Titanium Aneurysm Clip II
Aneurysm clipping is a surgical procedure used to treat brain aneurysms.
Rate of permanent aneurysm occlusions
Rate of complete permanent aneurysm occlusions according to Molyneux et al, 2005, where the category of occlusion is selected as "Complete occlusion".
Time frame: Up to 12 months
Incidence of adverse events
The number and percentage of subjects experiencing any adverse event. Each adverse event type, including severity will be reported.
Time frame: up to 60 months
Change in Modified Rankin Scale
The mean, standard deviation, median, minimum, maximum, and number of evaluable observations will be reported for baseline and to each follow up visit using descriptive statistics.The absolute change from baseline will be calculated for each subject at follow up visits.
Time frame: through 60 months
Amount of aneurysm retreatments
The amount of aneurysm retreatments will be reported as 0, 1 and \>=2 retreatments through each follow up visit.
Time frame: through 60 months
Procedure success rate
Rate of successful aneurysm occlusions per Molyneux classification "Complete occlusion" while using a permanent clip. Frequency counts and percentages of subjects, as well as 95% confidence intervals for the percentages will be presented.
Time frame: within 1 week after clipping
Rate of successful applications of temporary clips
Subjects that experience a successful aneurysm occlusion according to Molyneux classification "Complete occlusion" while using temporary clips.
Time frame: Within 1 week after clipping
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.
Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 22 months is below that.
Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.